Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal.
Technical aspects and results of the dosimetric assessments of postoperative radioiodine ablation in the framework of an international, prospective, controlled, randomized, comparative study of the effectiveness of ablation therapy with 3.7 GBq (131)I in differentiated thyroid cancer after stimulation with recombinant human TSH (rhTSH) or by thyroid hormone withdrawal (THW) are presented.


METHODS
Sixty-three patients were randomized after thyroidectomy to either the THW or the rhTSH group. Scintigraphic neck images were acquired starting 48 h after radioiodine administration to assess biokinetics in the thyroid remnant. The activity in blood samples was quantified and data from whole-body probe measurements and scintigraphic whole-body scans were combined to deduce retention curves in blood and whole body, respectively. The absorbed dose to the blood was calculated using a modified approach based on the formalism of the MIRD Committee of the Society of Nuclear Medicine.


RESULTS
The effective half-time in the remnant thyroid tissue was significantly longer after rhTSH than THW (67.6 +/- 48.8 vs. 48.0 +/- 52.6 h, respectively; P = 0.01), whereas the observed differences of the mean 48-h (131)I uptakes (0.5% +/- 0.7% vs. 0.9% +/- 1.0% after THW; P = 0.1) and residence times (0.9 +/- 1.3 vs. 1.4 +/- 1.5 h after THW; P = 0.1) between the rhTSH and THW groups were not statistically significant. The specific absorbed dose to the blood was significantly (P <0.0001) lower after administration of rhTSH (mean, 0.109 +/- 0.028 mGy/MBq; maximum, 0.18 mGy/MBq) than after THW (mean, 0.167 +/- 0.061 mGy/MBq; maximum, 0.35 mGy/MBq), indicating that higher activities of radioiodine might be safely administered after exogenous stimulation with rhTSH.


CONCLUSIONS
Indication of an influence of the residence time of radioiodine in the blood on the fractional uptake into thyroid remnant was found. A novel regimen is proposed in which therapeutic activities to be administered are determined from the individual specific blood dose.
Hänscheid
Heribert
H
Klinik und Poliklinik für Nuklearmedizin, Universität Würzburg, D-97080 Würzburg, Germany. haenscheid@nuklearmedizin.uni-wuerzburg.de
Lassmann
Michael
M
Luster
Markus
M
Thomas
Stephen R
SR
Pacini
Furio
F
Ceccarelli
Claudia
C
Ladenson
Paul W
PW
Wahl
Richard L
RL
Schlumberger
Martin
M
Ricard
Marcel
M
Driedger
Al
A
Kloos
Richard T
RT
Sherman
Steven I
SI
Haugen
Bryan R
BR
Carriere
Vincent
V
Corone
Carine
C
Reiners
Christoph
C
D000328:Adult; D006801:Humans; D007391:International Cooperation; D007457:Iodine Radioisotopes / Q000493:pharmacokinetics* / Q000627:therapeutic use; D011446:Prospective Studies; D011879:Radiotherapy Dosage; D011994:Recombinant Proteins / Q000627:therapeutic use; D013961:Thyroid Gland / Q000187:drug effects / Q000473:pathology / Q000528:radiation effects*; D013964:Thyroid Neoplasms / Q000188:drug therapy / Q000378:metabolism* / Q000532:radiotherapy*; D013965:Thyroidectomy; D013972:Thyrotropin / Q000627:therapeutic use*; D013974:Thyroxine / Q000008:administration & dosage / Q000627:therapeutic use*; D014915:Whole-Body Counting
D007457:Iodine Radioisotopes; D011994:Recombinant Proteins; D013972:Thyrotropin; D013974:Thyroxine